PARP1 and prostate carcinoma: CX-5461 cooperates with PARP inhibitors in enhancing replication stress and inhibiting HGSOC cell growth in vitro and in vivo [97] and also in inhibiting tumor growth of HR proficient prostate cancer patient-derived xerographs in vivo [127], highlighting this combination as an exciting approach for ovarian and prostate cancer treatment.